Menu Back toSession 5 Track 2: Advances in CNS Delivery of Oligonucleotides

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 5 Track 2: Advances in CNS Delivery of Oligonucleotides

Session Chair(s)

Jeffrey  Foy, PhD

Jeffrey Foy, PhD

  • Vice President, Toxicology
  • PepGen Inc., United States
Lois M. Freed, PhD

Lois M. Freed, PhD

  • Director, Division of Pharmacology/Toxicology-Neuroscience (DPT-N), CDER
  • FDA, United States
This session will focus on current research efforts in the area of neurological diseases. Improved oligonucleotide delivery and pharmacokinetics/interspecies scaling for neurological assessment based on age and exposure levels will be the focus of the session
Learning Objective : At the conclusion of this session, participants should be able to:
  • Discuss the new areas of oligonucleotide research and potential treatments for neurological disorders
  • Better understand mechanisms of CNS uptake and pharmacokinetics of oligonucleotides
  • Identify nonclinical study design considerations for nonclinical studies of oligonucleotides for CNS disorders


Lan  Dang, PhD

Expanding the Reach of RNAi Therapeutics

Lan Dang, PhD

  • Senior Scientist
  • Alnylam Pharmaceuticals, United States
Daniel  Norris, PhD, RPh

Comparison of PK Exposure Between Juvenile and Adult Animals After Intrathecal Administration

Daniel Norris, PhD, RPh

  • Executive Director, Pharmacokinetics and Clinical Pharmacology
  • Ionis Pharmaceuticals , United States
Branden  Ryu, PhD

Overcoming the Blood–Brain Barrier for RNA Therapeutics

Branden Ryu, PhD

  • Cheif Executive Officer
  • BIORCHESTRA Co., Ltd., Korea, Republic of